

## Board of Directors Meeting - Cover Sheet

<b>Subject:</b>	Research and Development Performance Report – Q1 2022/23		Date: 7 <sup>th</sup> July 2022	
<b>Prepared By:</b>	Alison Steel, Head of Research and Innovation			
<b>Approved By:</b>	Elizabeth Gemmill, Research and Innovation Director			
<b>Presented By:</b>	Elizabeth Gemmill, Research and Innovation Director/Terri Ann Sewell, Research Operations Manager			
<b>Purpose</b>				
<p>To present the Research and Innovation Quarterly Performance Report and draft 5-year R&amp;I strategy – <b>For review and comment by Trust Board</b></p> <p>Update and assurance on performance KPI's and financial position</p> <p>Update on recovery and growth of the SFH research portfolio</p> <p>Overview of research impacts and outcomes 2019-2022</p>			<b>Decision</b>	
			<b>Approval</b>	X
			<b>Assurance</b>	X
<b>Strategic Objectives</b>				
<b>To provide outstanding care</b>	<b>To promote and support health and wellbeing</b>	<b>To maximise the potential of our workforce</b>	<b>To continuously learn and improve</b>	<b>To achieve better value</b>
X		X	X	X
<b>Overall Level of Assurance</b>				
	<b>Significant</b>	<b>Sufficient</b>	<b>Limited</b>	<b>None</b>
		X		
<b>Risks/Issues</b>				
<b>Financial</b>	<ul style="list-style-type: none"> <li>Confirmed £755,435.10 EMCRN 2022/23 budget – rollover, no enhancements</li> <li>Commercial income in 22/23 Q1 for re-investment - £23,750.30</li> </ul>			
<b>Patient Impact</b>	<ul style="list-style-type: none"> <li>468 participants recruited into research studies</li> </ul>			
<b>Staff Impact</b>	<ul style="list-style-type: none"> <li>Collaboration with Nottingham Trent University to support development of clinical academic careers and research exposure for clinical staff</li> </ul>			
<b>Services</b>	<ul style="list-style-type: none"> <li>Support Clinical Divisions with research engagement</li> <li>CRF Transformation in progress</li> </ul>			
<b>Reputational</b>	<ul style="list-style-type: none"> <li>Retain a strong reputation for research delivery, re set and recovery</li> <li>Leading the way with collaboration with GP practises, HEI's and other NHS organisations to increase Research opportunities</li> <li>Leading on multi-site clinical trial</li> </ul>			
<b>Committees/groups where this item has been presented before</b>				
None				
<b>Executive Summary</b>				
<b>Performance Metrics</b>				
<ul style="list-style-type: none"> <li>468 participants recruited into research studies, 64 studies on the SFH portfolio</li> <li>Confirmed £755,435.10 EMCRN 2022/23 budget.</li> <li>Commercial income at Q1 £23,750.30</li> </ul>				

### **Patient Experience -**

Not included on Q1 2022/23 performance report due to insufficient data /inability to access full data at the time of submission.

### **Research and Innovation 2022-2027 - “Research is for Everyone”**

- 1. Place** - Delivering high quality research requires high quality infrastructure. We will invest in our research infrastructure and create a new research facility
- 2. Progress** - Over the next five years we will transform our approach to managing research at SFH to ensure the best use of resources and to maximise research opportunities
- 3. People** - Research is for “Everyone”, patients, carers, staff and our community. To deliver world class research we need to make it easier for people to get involved at any level.
- 4. Partnership** - Partnership and integrated working are key to research growth, sustainability and innovation